Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vismodegib -

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vismodegib 150mg;   - capsule - 150 mg - active: vismodegib 150mg   excipient: gelatin iron oxide black iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17822 opacode black s-1-17823 povidone purified talc sodium laurilsulfate sodium starch glycolate titanium dioxide - indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vismodegib, quantity: 150 mg - capsule, hard - excipient ingredients: purified talc; iron oxide red; gelatin; sodium starch glycollate; microcrystalline cellulose; titanium dioxide; iron oxide black; shellac; lactose monohydrate; povidone; magnesium stearate; sodium lauryl sulfate - erivedge is indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.

Canada - English - Health Canada

bayer inc - levonorgestrel - insert (extended-release) - 13.5mg - levonorgestrel 13.5mg - contraceptives

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - norethindrone 0.35 mg - progestin-only oral contraceptives are indicated for the prevention of pregnancy. if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception.   % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year method (1) typical use (2) perfect use (3) (4) no method4 85 85 spermicides 28 18 42 fertility awareness-based methods 24 47 standard days method6 5 twoday method6 4 ovulation method6 3 symptothermal method6 0.4 withdrawal 22 4 46 sponge 36 parous women 24 20 nulliparous women 12 9 condom7 female (fc) 21 5 41 male 18 2 43 diaphragm8 12 6 57 combined pill and progestin-only pill 9 0.3 67 norelgestromin and ethinyl estradiol patch 9 0.3 67 nuvaring 9 0.3 67 depo-provera 6 0.2 56 intrauterine contraceptives paragard (copper t) 0.8 0.6 78 mirena (lng) 0.2 0.2 80 implanon 0.05 0.05 84 female sterilization 0.5 0.5 100 male sterilization 0.15 0.10 100 notes: norethindrone tablets have not been studied for and are not indicated for use in emergency contraception. progestin-only oral contraceptives (pops) should not be used by women who currently have the following conditions: